Oesterling J E, Tekchandani A H, Martin S K, Bergstralh E J, Reichstein E, Diamandis E P, Yemoto C, Stamey T A
Michigan Prostate Institute and University of Michigan, Ann Arbor, USA.
J Urol. 1996 May;155(5):1658-60.
The periurethral glands are known to produce prostate specific antigen (PSA). With ultra-sensitive assays now routinely available, it is necessary to determine if the periurethral glands significantly influence serum PSA concentration after radical prostatectomy.
Serum PSA levels of 46 men, 51 to 89 years old (median age 67) who underwent radical cystoprostatectomy and total urethrectomy, were compared with those of 92 men 46 to 91 years old (median age 67) who underwent radical cystoprostatectomy only. All men had transitional cell carcinoma of the bladder without gross or microscopic evidence of prostate cancer and all underwent ileal conduit diversion. Serum was obtained at least 1 year postoperatively. Each specimen was analyzed using the Tosoh, Immulite, and Yu and Diamandis ultra-sensitive PSA assays with analytical detection limits of 0.02 ng./ml., 0.004 ng./ ml. and 0.002 ng./ml., respectively.
Median PSA for the radical cystoprostatectomy with urethrectomy group was 0.00 ng./ml. (range 0.00 to 0.14) for each of the 3 assays. For the radical cystoprostatectomy only group the median Tosoh and Immulite PSA assay levels were 0.01 ng./ml. (range 0.00 to 0.22), and median Yu and Diamandis PSA assay level was 0.00 ng./ml. (range 0.00 to 0.31).
The greatest difference in median PSA levels that could be found between men with and without periurethral glands when using 3 different ultra-sensitive assays was 0.01 ng./ml., indicating that the periurethral glands do not have a clinically significant effect on serum PSA concentration after radical prostatectomy. Thus, a serum PSA level above the residual cancer detection limit following radical prostatectomy, even if obtained with a ultra-sensitive assay, reflects either malignant or benign residual prostatic tissue, rather than the presence of periurethral glands.
已知尿道周围腺体可产生前列腺特异性抗原(PSA)。鉴于现在常规可获得超灵敏检测方法,有必要确定在根治性前列腺切除术后尿道周围腺体是否会显著影响血清PSA浓度。
将46例年龄在51至89岁(中位年龄67岁)接受根治性膀胱前列腺切除术和全尿道切除术的男性的血清PSA水平,与92例年龄在46至91岁(中位年龄67岁)仅接受根治性膀胱前列腺切除术的男性的血清PSA水平进行比较。所有男性均患有膀胱移行细胞癌,无前列腺癌的大体或显微镜下证据,且均接受回肠导管改道术。术后至少1年采集血清。每个标本分别使用东曹、免疫发光法以及余和迪亚曼迪斯超灵敏PSA检测方法进行分析,分析检测限分别为0.02 ng/ml、0.004 ng/ml和0.002 ng/ml。
对于接受根治性膀胱前列腺切除术加尿道切除术的组,三种检测方法的PSA中位数均为0.00 ng/ml(范围为0.00至0.14)。对于仅接受根治性膀胱前列腺切除术的组,东曹和免疫发光法检测的PSA中位数水平为O.O1 ng/ml(范围为0.00至0.22),余和迪亚曼迪斯检测的PSA中位数水平为0.00 ng/ml(范围为0.00至0.31)。
使用三种不同的超灵敏检测方法时,有或无尿道周围腺体的男性之间可发现的PSA中位数水平最大差异为0.01 ng/ml,这表明尿道周围腺体在根治性前列腺切除术后对血清PSA浓度没有临床显著影响。因此,根治性前列腺切除术后血清PSA水平高于残余癌检测限,即使是通过超灵敏检测获得的,也反映了恶性或良性的残余前列腺组织,而非尿道周围腺体的存在。